HAC (Russian)
RSCI (Russian)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services


DOI: https://doi.org/10.29296/25877305-2021-12-05

N. Kunitskaya, MD, PhD. I.I. Mechnikov North-Western State Medical University, Ministry of
Health of Russia, Saint Petersburg

Osteoarthritis (OA) is a chronic progressive joint disease that poses a serious general medical and social problem. The disease is associated with an increased risk of death and requires the earliest possible appointment of therapy. According to modern recommendations, the treatment of patients should include non-pharmacological and pharmacological methods. The article discusses the basic therapy of OA, including symptomatic delayed-action drugs (SYSADOA), paracetamol, nonsteroidal anti-inflammatory drugs, intra-articular administration of hyaluronic acid and glucocorticosteroids, as well as issues of anesthesia for severe pain syndrome. Total knee replacement is recommended only for patients with the last stage of OA.

modern therapy
symptomatic drugs
chondroitin sulfate
regenerative methods

  1. Abramoff B., Caldera F.E. Osteoarthritis: pathology, diagnosis, and treatment options. Med Clin North Am. 2020; 104 (2): 293–311. DOI: 10.1016/j.mcna.2019.10.007
  2. Avouac J., Gossec L., Dougados M. Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2007; 15 (8): 957–65. DOI: 10.1016/j.joca.2007.02.006
  3. Bhala N., Emberson J., Merhi A. et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382 (9894): 769–79. DOI: 10.1016/S0140-6736(13)60900-9
  4. Bruyère O., Honvo G., Veronese N. et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49 (3): 337–50. DOI: 10.1016/j.semarthrit.2019.04.008
  5. Bruyère O., Cooper C., Pelletier J.P. et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016; 45 (4 Suppl): S3–11. DOI: 10.1016/j.semarthrit.2015.11.010
  6. Bruyère O., Honvo G., Veronese N. et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49 (3): 337–50. DOI: 10.1016/j.semarthrit.2019.04.008
  7. Carlesso L.C., Segal N.A., Frey-Law L. et al. Pain susceptibility phenotypes in those free of knee pain with or at risk of knee osteoarthritis: the multicenter osteoarthritis study. Arthritis Rheum. 2019; 71 (4): 542–9. DOI: 10.1002/art.40752
  8. Cleveland R.J., Alvarez C., Schwartz T.A. et al. The impact of painful knee osteoarthritis on mortality: a community-based cohort study with over 24 years of follow-up. Osteoarthritis Cartilage. 2019; 27 (4): 593–602. DOI: 10.1016/j.joca.2018.12.008
  9. Corsi M., Alvarez C., Callahan L.F. et al. Contributions of symptomatic osteoarthritis and physical function to incident cardiovascular disease. BMC Musculoskelet Disord. 2018; 19 (1): 393. DOI: 10.1186/s12891-018-2311-4
  10. da Costa B.R., Reichenbach S., Keller N. et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017; 390 (10090): 21–33. DOI: 10.1016/S0140-6736(17)31744-0
  11. DeRogatis M., Anis H.K., Sodhi N. et al. Non-operative treatment options for knee osteoarthritis. Ann Transl Med. 2019; 7 (Suppl. 7): S245. DOI: 10.21037/atm.2019.06.68
  12. Dorleijn D.M.J., Luijsterburg P.A.J., Reijman M. et al. Intramuscular glucocorticoid injection versus placebo injection in hip osteoarthritis: a 12-week blinded randomised controlled trial. Ann Rheum Dis. 2018; 77 (6): 875–82. DOI: 10.1136/annrheumdis-2017-212628
  13. Felson D.T. Tramadol and mortality in patients with osteoarthritis. JAMA. 2019; 322 (5): 465–6. DOI: 10.1001/jama.2019.7216
  14. Fleischmann R.M., Bliddal H., Blanco F.J. et al. A phase II trial of lutikizumab, an anti-inter-leukin-1alpha/beta dual variable domain immunoglobulin, in knee osteoarthritis patients with synovitis. Arthritis Rheum. 2019; 71 (7): 1056–69. DOI: 10.1002/art.40840
  15. Filardo G., Kon E., Roffi A. et al. Platelet-rich plasma: why intra-articular? A systematic review of preclinical studies and clinical evidence on PRP for joint degeneration. Knee Surg Sports Traumatol Arthrosc. 2015; 23: 2459–74. DOI: 10.1007/s00167-013-2743-1
  16. Filardo G., Di Matteo B., Di Martino A. et al. Platelet-rich plasma intra-articular knee injections show no superiority versus viscosupplementation: a randomized controlled trial. Am J Sports Med. 2015; 43: 1575–82. DOI: 10.1177/0363546515582027
  17. Fingleton C., Smart K., Moloney N. et al. Pain sensitization in people with knee osteoarthritis: a systematic review and meta-analysis. Osteoarthritis Cartilage. 2015; 23 (7): 1043–56. DOI: 10.1016/j.joca.2015.02.163
  18. Fukawa T., Yamaguchi S., Akatsu J. et al. Safety and Efficacy of Intra-articular Injection of Platelet-Rich Plasma in Patients With Ankle Osteoarthritis. Foot Ankle Int. 2017; 38 (6): 596–604. DOI: 10.1177/1071100717700377
  19. Fuggle N., Curtis E., Shaw S. et al. Safety of Opioids in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019; 36 (Suppl. 1): 129–43. DOI: 10.1007/s40266-019-00666-9
  20. Hawker G.A., Croxford R., Bierman A.S. et al. All-cause mortality and serious cardiovascular events in people with hip and knee osteoarthritis: a population based cohort study. PLoS One. 2014; 9 (3): 286–91. DOI: 10.1371/journal.pone.0091286
  21. Hochberg M.C., Martel-Pelletier J., Monfort J. et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016; 75 (1): 37–44. DOI: 10.1136/annrheumdis-2014-206792
  22. Honvo G., Reginster J.Y., Rannou F. et al. Safety of intra-articular hyaluronic acid injections in osteoarthritis: outcomes of a systematic review and metaanalysis. Drugs Aging. 2019; 36 (Suppl. 1): 45–6. DOI: 10.1007/s40266-019-00657-w
  23. Jin Y., Smith C., Monteith D. et al. CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial. Osteoarthritis Cartilage. 2018; 26 (12): 1609–18. DOI: 10.1016/j.joca.2018.08.019
  24. Kloppenburg M., Peterfy C., Haugen I.K. et al. Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1alpha and anti-interleukin-1beta dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Ann Rheum Dis. 2019; 78 (3): 413–20. DOI: 10.1136/annrheumdis-2018-213336
  25. Kloppenburg M., Ramonda R., Bobacz K. et al. Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled. Ann Rheum Dis. 2018; 77 (12): 1757–64. DOI: 10.1136/annrheumdis-2018-213202
  26. Laver L., Marom N., Dnyanesh L. et al. PRP for Degenerative Cartilage Disease: A Systematic Review of Clinical Studies. Cartilage. 2017; 8 (4): 341–64. DOI: 10.1177/1947603516670709
  27. Leopoldino A.O., Machado G.C., Ferreira P.H. et al. Paracetamol versus placebo for knee and hip osteoarthritis. Cochrane Database Syst Rev. 2019; 2: CD013273. DOI: 10.1002/14651858.CD013273
  28. Machado G.C., Maher C.G., Ferreira P.H. et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ. 2015; 350: h1225. DOI: 10.1136/bmj.h1225
  29. McAlindon T.E., LaValley M.P., Harvey W.F. et al. Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. JAMA. 2017; 317 (19): 1967–75. DOI: 10.1001/jama.2017.5283
  30. Mohan G.C., Zhang H., Bao L. et al. Diacerein inhibits the pro-atherogenic & pro-inflammatory effects of IL-1 on human keratinocytes & endothelial cells. PLoS One. 2017; 12 (3): e0173981. DOI: 10.1371/journal.pone.0173981
  31. Navarro-Sarabia F., Coronel P., Collantes E. et al. A 40-month multicentre, randomized placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project. Ann Rheum Dis. 2011; 70: 1957–62. DOI: 10.1136/ard.2011.152017
  32. Nelson A.E., Allen K.D., Golightly Y.M. et al. A systematic review of recommendations and guidelines for the management of osteoarthritis: the chronic osteoarthritis management initiative of the U.S. bone and joint initiative. Semin Arthritis Rheum. 2014; 43 (6): 701–12. DOI: 10.1016/j.semarthrit.2013.11.012
  33. Permuy M., Guede D., Lopez-Pena M. et al. Effects of diacerein on cartilage and subchondral bone in early stages of osteoarthritis in a rabbit model. BMC Vet Res. 2015; 11: 143. DOI: 10.1186/s12917-015-0458-x
  34. Schaefert R., Welsch P., Klose P. et al. Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Schmerz. 2015; 29 (1): 47–59. DOI: 10.1007/s00482-014-1451-1
  35. Shelbaya A., Solem C.T., Walker C. et al. The economic and clinical burden of early versus late initiation of celecoxib among patients with osteoarthritis. Clinicoecon Outcomes Res. 2018; 10: 213–22. DOI: 10.2147/CEOR.S140208
  36. Stevens R.M., Ervin J., Nezzer J. et al. Randomized, double-blind, placebo-controlled trial of intra-articular CNTX-4975 (trans-capsaicin) for pain associated with osteoarthritis of the knee. Arthritis Rheum. 2019; 71 (9): 1524–33. DOI: 10.1002/art.40894
  37. Steinecker-Frohnwieser B., Weigl L., Kullich W. et al. The disease modifying osteoarthritis drug diacerein is able to antagonize pro inflammatory state of chondrocytes under mild mechanical stimuli. Osteoarthritis Cartilage. 2014; 22 (7): 1044–52. DOI: 10.1016/j.joca.2014.05.008
  38. Turkiewicz A., Kiadaliri A.A., Englund M. Cause-specific mortality in osteoarthritis of peripheral joints. Osteoarthritis Cartilage. 2019; 27 (6): 848–54. DOI: 10.1016/j.joca.2019.02.793
  39. Wang Y., Stephen Hall S., Hanna F. et al. Effects of Hylan G-F 20 supplementation on cartilage preservation detected by magnetic resonance imaging in osteoarthritis of the knee: a two-year single-blind clinical trial. BMC Musculoskelet Disord. 2011; 12: 195–204. DOI: 10.1186/1471-2474-12-195
  40. Van Dalen S.C., Blom A.B., Slöetjes A.W. Interleukin-1 is not involved in synovial inflammation and cartilage destruction in collagenase-induced osteoarthritis. Osteoarthritis Cartilage. 2017; 25 (3): 385–96. DOI: 10.1016/j.joca.2016.09.009
  41. Zeng C., Lane N.E., Hunter D.J. et al. Intra-articular corticosteroids and the risk of knee osteoarthritis progression: results from the Osteoarthritis Initiative. Osteoarthritis Cartilage. 2019; 27 (6): 855–62.
  42. Peshehonova L.K., Peshehonov D.V., Krasjukov P.A. Klinicheskaja effektivnost' primenenija preparatov Osteomed, Osteomed Forte, Osteo-Vit D3 u bol'nyh vtorichnym osteoporozom pri revmatoidnom artrite. Vrach. 2020; 31 (4): 68–74 [Peshekhonova L., Peshekhonov D., Krasyukov P. The clinical efficiency of using Osteomed, Osteomed Forte, and Osteo-Vit D3 in patients with secondary osteoporosis in rheumatoid arthritis. Vrach. 2020; 31 (4): 68–74 (in Russ.)]. DOI: 10.29296/25877305-2020-04-12
  43. Strukov V., Elistratov D., Kislov A. i dr. Osteoporoz v geriatricheskoj praktike. Vrach. 2018; 29 (6): 26–30 [Strukov V., Elistratov D., Kislov A. et al. Osteoporosis in geriatric practice. Vrach. 2018; 29 (6): 26–30 (in Russ.)]. DOI: 10.29296/25877305-2018-06-05